{"prompt": "['PREDM', 'Page 19', 'effects) and be enrolled in a digitally delivered lifestyle intervention program', 'through an existing digital partner, after informed consent has been obtained.', '3.6 Compensation', 'Participants will be compensated for their time and effort. They will receive', '$150 for completion of study visit 2 (week 12) and 3 (week 24). Study visit', '1/Screening Visit (Day 0) will occur at the time of a regularly scheduled SJLIFE', 'Core visit and include the regular SJLIFE visit compensation.', '4.0 DESIGN AND METHODS', '4.1 Design and Study Overview', 'This is a single-arm, open-label intervention pilot trial (Figure 2) to assess the primary', 'endpoints of: 1) feasibility and safety of a combined metformin + digitally delivered', 'lifestyle change program, and 2) effects on glycemic control, insulin resistance,', 'weight and anthropometric measures and physical activity in survivors of childhood', 'cancer, aged 18-<45 years, who are prediabetic. The objective of this study is to', 'provide feasibility data and initial evidence for efficacy in an efficient pilot, open', 'label setting. If successful, these results will provide necessary preliminary data for a', 'randomized, phase 2b trial of efficacy. In the general population, metformin and', 'lifestyle change have each demonstrated efficacy to reduce the incidence of diabetes', 'by 40-50% among prediabetic adults aged 25-44 years.', '12', 'Initial version, dated: 04-10-20', 'IRB approkB', \"St. Jude date Children's Research Hospital\", 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 20', 'PREDM Study Schema', 'Figure: 2', 'Screening', '1', '2', '4', '8', '12', '16', '20', '24', 'Study Schema', 'Prediabetic/ Adult', 'Survivor of', 'Regimen M +', 'Childhood Cancer', 'Lifestyle Intervention', 'Enrolled in SUFE', 'Metformin ER500mg/day', '+', 'Digitally deliveredlifestyle', 'Age 18-<45years', 'dhangeprogram', 'Cinical and Lab Studies', 'Screening', '2', '4', '8', '12', '16', '20', '24', 'Cancer treatment history', 'History and physical', 'X', 'X', 'Anthropometricsa', 'Xe', 'X', 'X', 'Frailty measures', 'Xe', 'X', 'Fasting blood work C', 'Xe', 'X', 'X', 'Physical activity by 7-day accelerometer data', 'Self-Administered Questionnaires', 'Demographic, medical & family history', 'Xe', 'X', 'X', 'SF36 for HRQCL', 'Xe', 'X', 'X', 'DAST and AUDIT', 'X', 'Motivation to change', 'X', 'Barriersto participation', 'X', 'Treatment Management and Adherence Monitoring', 'Lifestyle change enrollment', 'X', 'Metformin ER500mgtest dose', 'X', 'Study tablets dispensed', 'X', 'X', 'X', 'X', 'X', 'X', 'Follow-up phone call d', 'X', 'X', 'X', 'X', 'Symptomlog', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Medication adherence log', 'X', 'X', 'X', 'Lifestyle change adherencel', 'X', 'Week 1 will be when the participant beginsmetformin 500 mg/ day and the lifestyle change program and may occur up to 28', 'daysafter screening assessments Anthropometrics: BMI, body1 fat % waist circumference b Frailty measures: walking speed,', 'hand grip strength (body fat % C Fasting blood work: glucose, insulin, hemoglobin A1c, IGF-BP1, complete metabolic panel', '(CMP), lactate, cystatin C, complete blood count, lipid panel. Follow-up phone call: conduct pill count, confirm medication', 'tolerance prior to titration, complete symptomlog, arrange medication refill. e Repeat only if screening>30daysprior.', 'f Limited interim medical history induding medications', '*In the above schema, the 2 week visit will be conducted between +/- 4 days (between 10', 'and 18 days) and all monthly assessments including phone calls, labs and on-campus visits', 'at weeks 4, 8, 12, 16, 20 and 24 will occur +/-7 days from the planned date.', '4.2 Definition and assessment of outcome measures', '4.2.1 Primary Outcomes of PREDM', 'Adherence for feasibility: A participant will be considered adherent to the', 'combined intervention if they are 80% adherent to metformin ER and complete', '60% of the digitally-delivered core-curriculum. Metformin adherence will be', 'monitored using virtual pill counts, the protocol will be adapted from Kalichman et', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}